Market outlook of the global liver diseases therapeutics market
Technavio’s market research analyst has estimated the global market for liver diseases therapeutics to grow rapidly during the forecast period. Factors like the increased prevalence of liver cancer in developed countries and the expected entry of pipeline drugs into the market are expected to result in this market’s impressive CAGR of more than 15% by 2019.
The high-unmet medical need of the populace is a key driver for the growth of this market. Drugs that are currently available in this market have adverse side effects and, therefore, results in increased noncompliance among individuals with liver diseases. Additionally, since the availability of hepatitis vaccine is low in many regions, the medical needs of the populace remains unmet for extended periods of time.
Competitive landscape and key vendors
This market is highly competitive due to the presence of numerous vendors who have develop branded, generic, and off-label drugs to cure liver diseases. Competition in this market is expected to increase during the forecast period due to the launch of pipeline drugs under different developmental stages.
Key vendors in this market are -
- F. Hoffmann-La Roche
- Gilead Sciences
- GlaxoSmithKline
- Johnson & Johnson
- Merck
Other prominent vendors are Achillion Pharmaceuticals, AbbVie, Advinus, Angion Biomedica, AstraZeneca, Bayer, BiOrion, Boehringer Ingelheim , Bristol-Myers Squibb, Celsion, Conatus, Digna Biotech, Dynavax Technologies, Eli Lilly, Galectin Therapeutics, Genfit, GenKyoTex, Isis Pharmaceuticals, Janssen Pharmaceuticals, La Jolla Pharmaceutical, LG Life Sciences, Kaketsuken, Mitsubishi Tanabe Pharma, Nitto Denko, Novartis, Onyx Pharmaceuticals (a subsidiary of Amgen), Phenex Pharmaceuticals, Promedior, Promethera Biosciences, ProMetic Life Sciences, Raptor Pharmaceuticals, Shenzhen Kangtai Biological Products, TCM Biotech, Tobira Therapeutics, VBL Therapeutics, Verva Pharmaceuticals, Virobay, and Zafgen.
Segmentation by disease indication and analysis of the liver diseases therapeutics market
- Hepatitis
- Liver cirrhosis
- Liver cancer
In this market analysis, Technavio market research analysts have estimated the Hepatitis segment to account for more than 85% of the total market share by 2019. Hepatitis can be of types A, B, C, D, and E, among which hepatitis C is expected to have the highest prevalence during the forecast period. Viral infections, alcoholism, obesity, and diabetes are envisaged to be the most common causes of liver disease.
Geographical segmentation of the liver diseases therapeutics market
The Americas are expected to account for the largest market share during the forecast period followed by EMEA and the APAC regions. High medical unmet needs of the populace coupled with the augmented prevalence of liver diseases in the Americas are envisaged to account for its high market share of nearly 49% during the forecast period.
Key questions answered in the report include
- What will the market size and the growth rate be in 2019?
- What are the key factors driving the global liver diseases therapeutics market?
- What are the key market trends impacting the growth of the global liver diseases therapeutics market?
- What are the challenges to market growth?
- Who are the key vendors in the global liver diseases therapeutics market?
- What are the market opportunities and threats faced by the vendors in the global liver diseases therapeutics market?
- Trending factors influencing the market shares of the EMEA, Americas, and APAC?
- What are the key outcomes of the five forces analysis of the global liver diseases therapeutics market
Technavio also offers customization on reports based on specific client requirement.
Related reports
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
- Market overview
- Top-vendor offerings
PART 03: Market research methodology
- Research methodology
- Economic indicators
PART 04: Introduction
PART 05: Disease overview
- Hepatitis
- Liver cancer
- Liver cirrhosis
- Nonalcoholic fatty liver disease
PART 06: Market landscape
- Global liver diseases therapeutics market
PART 07: Market segmentation by disease
- Hepatitis
- Liver cirrhosis
- Liver cancer
- Nonalcoholic fatty liver disease
PART 08: Global hepatitis therapeutics market
- Global hepatitis A therapeutics market
- Global hepatitis B therapeutics market
- Global hepatitis C therapeutics market
PART 09: Global liver cancer therapeutics market
PART 10: Global nonalcoholic fatty liver disease therapeutics market
PART 11: Global liver cirrhosis therapeutics market
PART 12: Market segmentation by type of molecule
- Biologics
- Small molecules
PART 13: Geographical segmentation
- Liver diseases therapeutics market in Americas
- Liver diseases therapeutics market in EMEA
- Liver diseases therapeutics market in APAC
PART 14: Market drivers
PART 15: Impact of drivers
PART 16: Market challenges
PART 17: Impact of drivers and challenges
PART 18: Market trends
PART 19: Vendor landscape
- Competitive scenario
- Market share analysis 2014
- Other and future prominent vendors
PART 20: Key vendor analysis
- F. Hoffmann-La Roche
- Gilead Sciences
- GlaxoSmithKline
- Johnson & Johnson
- Merck
PART 21: Appendix
Part 22: Explore Technavio
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
- Manufacturers and suppliers
- Channel partners
- Industry experts
- Strategic decision makers
Secondary sources
- Industry journals and periodicals
- Government data
- Financial reports of key industry players
- Historical data
- Press releases
DATA ANALYSIS
Data Synthesis
- Collation of data
- Estimation of key figures
- Analysis of derived insights
Data Validation
- Triangulation with data models
- Reference against proprietary databases
- Corroboration with industry experts
REPORT WRITING
Qualitative
- Market drivers
- Market challenges
- Market trends
- Five forces analysis
Quantitative
- Market size and forecast
- Market segmentation
- Geographical insights
- Competitive landscape